β2-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic lateral sclerosis (ALS)

@article{Bartus20162AdrenoceptorAA,
  title={$\beta$2-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic lateral sclerosis (ALS)},
  author={Raymond T. Bartus and Alexandre B{\'e}tourn{\'e} and Anthony S. Basile and Bethany L Peterson and Jonathan D. Glass and Nicholas M. Boulis},
  journal={Neurobiology of Disease},
  year={2016},
  volume={85},
  pages={11-24}
}
Amyotrophic lateral sclerosis (ALS) is a chronic and progressive neuromuscular disease for which no cure exists and better treatment options are desperately needed. We hypothesize that currently approved β2-adrenoceptor agonists may effectively treat the symptoms and possibly slow the progression of ALS. Although β2-agonists are primarily used to treat asthma, pharmacologic data from animal models of neuromuscular diseases suggest that these agents may have pharmacologic effects of benefit in… 
Beta-agonist stimulation ameliorates the phenotype of spinal and bulbar muscular atrophy mice and patient-derived myotubes
TLDR
Results indicate that β-agonist stimulation is a novel therapeutic strategy for SBMA, and improves muscle pathology, attenuated the glycolytic-to-oxidative metabolic alterations occurring in SBMA muscles and induced hypertrophy of both glyCOlytic and oxidative fibers.
Adrenoceptors Modulate Cholinergic Synaptic Transmission at the Neuromuscular Junction
TLDR
The elucidation of the molecular mechanisms by which the clinically relevant adrenoceptor activators and blockers regulate quantal acetylcholine release from the presynaptic nerve terminals and postsynaptic sensitivity may help in the design of highly effective and well-tolerated sympathomimetics for treating a number of neurodegenerative diseases accompanied by synaptic defects.
Could Sirtuin Activities Modify ALS Onset and Progression?
  • B. Tang
  • Biology, Medicine
    Cellular and Molecular Neurobiology
  • 2016
TLDR
It is important that the potentially beneficial effect of Sirtuins in ALS disease onset and progression are assessed in ALS models with TDP-43, FUS, and C9orf72 mutations.
Neuromuscular junction degeneration in muscle wasting
TLDR
Basic research has revealed that maintenance of neuromuscular junctions and a few signaling pathways are important in the context of age-dependent and other forms of muscle wasting.
β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure
TLDR
An animal model of acetylcholine receptor deficiency syndrome is used to show that beta-2 adrenergic receptor agonists ameliorate the damage to neuromuscular junction structure caused by prolonged anticholinesterase medication, and thereby counteract the decline in efficacy.
Adrenoceptors at the Frog Neuromuscular Junction: an Immunohistochemical Study
TLDR
The presence of different adrenoceptors at isolated preparations of frog cutaneous pectoris muscle by using methods of immunohistochemistry expands the understanding of the endogenous mechanisms of cholinergic neurotransmission regulation and elucidates the aspects of the mechanisms of action of adrenergic agonists.
&agr;‐Cedrene, a Newly Identified Ligand of MOR23, Increases Skeletal Muscle Mass and Strength
SCOPE Skeletal muscle atrophy is a common and debilitating condition that lacks an effective therapy. In this study, the effects of α-cedrene are tested, a natural ligand of mouse olfactory receptor
α-Ionone attenuates high-fat diet-induced skeletal muscle wasting in mice via activation of cAMP signaling.
TLDR
It is found that α-ionone not only stimulated myogenesis but also attenuated palmitic-acid-induced atrophy of cultured skeletal myotubes, as evidenced by an increased myotube diameter and length, fusion index, and cellular protein content.
Sympathomimetics regulate quantal acetylcholine release at neuromuscular junctions through various types of adrenoreceptors
TLDR
The results have shown that the α1A, α1B, α2A, β1 adrenoreceptor subtypes are expressed in mouse diaphragm muscle containing neuromuscular synapses and sympathetic varicosities, and the action of blockers on quantal acetylcholine secretion indicates possible action of endogenous catecholamines on neurmuscular transmission.
Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability
  • M. Takamori
  • Chemistry, Medicine
    Frontiers in Molecular Neuroscience
  • 2020
TLDR
The study on MuSK ectodomains (Ig1/2 domains and CRD) recognized by antibodies suggested that the MuSK antibodies were pathologically heterogeneous due to their binding to multiple functional domains, which may affect the synaptic stability of MG patients.
...
1
2
3
...

References

SHOWING 1-10 OF 137 REFERENCES
The potential and the pitfalls of beta-adrenoceptor agonists for the management of skeletal muscle wasting.
TLDR
The therapeutic potential of stimulating the beta-adrenergic signaling pathway with beta-agonists is described, highlighting the beneficial effects on skeletal muscle structure and function and identifying some of the pitfalls associated with short- and long-term beta-agonist administration.
β2-Adrenergic agonists and the treatment of skeletal muscle wasting disorders.
TLDR
The purpose of this review is to present the biological and clinical significance of β2-agonists for the treatment of skeletal muscle wasting and the anti-atrophy effects of β1-agonist administration in several animal models and human pathologies associated with or leading to muscle wasting.
Can the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting?
TLDR
The primary objectives of the current review are to assess the mechanisms, both molecular and cell-associated, that may limit the anti-inflammatory efficacy of β2-agonists and to evaluate pharmacological strategies that may overcome these limitations.
A pilot trial with clenbuterol in amyotrophic lateral sclerosis
  • G. Soraru', E. Pegoraro, +6 authors C. Angelini
  • Medicine
    Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases
  • 2006
TLDR
This study was designed to test the safety and efficacy of clenbuterol in ALS patients already treated with riluzole and found that beta agonists may positively influence muscle bulk and strength in humans.
Therapeutic effects of clenbuterol in a murine model of amyotrophic lateral sclerosis
TLDR
The data suggest that clenbuterol offers therapeutic effects on ALS-related neuromuscular degeneration, and Responses in female G93A-SOD1 mice were favorable to those of males, suggesting synergistic effects between clen buterol and sex-specific factors.
Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease.
TLDR
The physiological significance ofbeta-adrenergic signaling in skeletal muscle is described and the proposed beneficial effects of beta-agonist administration on skeletal muscle along with some of the less desirable cardiovascular effects are examined.
The β2-adrenoceptor agonist clenbuterol elicits neuroprotective, anti-inflammatory and neurotrophic actions in the kainic acid model of excitotoxicity
TLDR
The β(2)-adrenoceptor agonist clenbuterol has anti-inflammatory and neurotrophic actions and elicits a neuroprotective effect in the KA model of neurodegeneration.
β2-Adrenergic Receptor Activation Prevents Rodent Dopaminergic Neurotoxicity by Inhibiting Microglia via a Novel Signaling Pathway
TLDR
Results demonstrate that administration of extremely low doses of salmeterol exhibit potent neuroprotective effects by inhibiting microglial cell activation through a β2AR/β-arrestin2–dependent but cAMP/protein kinase A-independent pathway.
β2-Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome
TLDR
A role for IGF1 and other growth factor deficits as an underlying mechanism of Rett syndrome is supported and β2-adrenergic receptor agonists are introduced as potential therapeutic agents for the treatment of the disorder.
β2-Adrenoceptor agonists in the regulation of mitochondrial biogenesis.
TLDR
The specificity and chemical rationale of a panel of β2-adrenoceptor agonists with regards to mitochondrial biogenesis is reported, with four unique features elucidating the spatial and chemical characteristics required to stimulate MB.
...
1
2
3
4
5
...